Novo Nordisk is phasing out Human Mixtard, India’s largest-selling insulin brand, along with other pen-based insulin products like Actrapid, Insulatard, and Xultophy. This decision is part of a global move to discontinue older generation insulin products and shift focus to newer, high-profit therapies.
The discontinuation will be gradual, expected to complete within six months, or once existing stocks are exhausted. Abbott India, the company’s marketing partner, has been informed of this transition. These changes could significantly impact India’s Rs 5,000 crore insulin market, where pre-filled pen devices are widely used for their convenience.
Though vial versions of Human Mixtard, Actrapid, and Insulatard will still be available, the move may create accessibility issues. Many diabetics prefer pen delivery for ease, dosage accuracy, and reduced stigma, especially in daily use scenarios.
This decision aligns with Novo Nordisk’s strategy to prioritize innovative products like Ozempic and Wegovy, which offer greater profitability and are expected to enter the Indian market soon.
